Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis

BACKGROUND: Cladribine is an effective immunotherapy for people with multiple sclerosis (pwMS). Whilst most pwMS do not require re-treatment following standard dosing (two treatment courses), disease activity re-emerges in others. The characteristics of pwMS developing re-emerging disease activity r...

Descripción completa

Detalles Bibliográficos
Autores principales: Allen-Philbey, Kimberley, De Trane, Stefania, MacDougall, Amy, Adams, Ashok, Bianchi, Lucia, Campion, Thomas, Giovannoni, Gavin, Gnanapavan, Sharmilee, Holden, David W., Marta, Monica, Mathews, Joela, Turner, Benjamin P., Baker, David, Schmierer, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638874/
https://www.ncbi.nlm.nih.gov/pubmed/37954917
http://dx.doi.org/10.1177/17562864231200627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638874/
https://www.ncbi.nlm.nih.gov/pubmed/37954917
http://dx.doi.org/10.1177/17562864231200627

Ejemplares similares